Leadership

Mr. Narachi joined the Ultragenyx board in February 2015. He previously served as president and chief executive officer of CODA Biotherapeutics, Inc. (August 2018 – October 2022) and currently serves as a director of CODA. He served as president, CEO and director of Orexigen Therapeutics, Inc. from March 2009 to July 2018. Before that, Mr. Narachi served as chair, CEO and president of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. In 2004, Mr. Narachi retired as an officer and vice president of Amgen Inc., where he served as general manager of Amgen’s Anemia Business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various senior positions throughout the organization over a 20-year career, including vice president of development and representative director for Amgen Japan; head of corporate strategic planning; chief operations officer of Amgen; and vice president, licensing and business development.

Mr. Narachi currently serves as a member of the board of BIO, the Biotechnology Innovation Organization, and previously served as a member of the board of directors of PhRMA, the Pharmaceutical Research and Manufacturers of America. He also previously served as the chairman of the board of directors of Celladon Corporation and a director of AMAG Pharmaceuticals, Inc. Mr. Narachi received a B.S. in biology and an M.A. in biology and genetics from the University of California, Davis. He received an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.